The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Open accessAbstract
The Eph receptor tyrosine kinases and their ephrin ligands have intriguing expression patterns in cancer cells and tumour blood vessels, which suggest important roles for their bidirectional signals in many aspects of cancer development and progression. Eph gene mutations probably also contribute to cancer pathogenesis. Eph receptors and ephrins have been shown to affect the growth, migration and invasion of cancer cells in culture as well as tumour growth, invasiveness, angiogenesis and metastasis in vivo. However, Eph signalling activities in cancer seem to be complex, and are characterized by puzzling dichotomies. Nevertheless, the Eph receptors are promising new therapeutic targets in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207247 · Cited by 211
RetractedThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Eph-Ephrin Bidirectional Signaling in Physiology and Disease
Pasquale, E. B. (2008) · Cell · doi:10.1016/j.cell.2008.03.011 · Cited by 1,252
Self-citationBatlle, E., Henderson, J. T., Beghtel, H., van den Born, M. M. W., Sancho, E., Huls, G., Meeldijk, J., Robertson, J., van de Wetering, M., Pawson, T., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01015-2 · Cited by 1,120
Eph receptor signalling casts a wide net on cell behaviour
Pasquale, E. B. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1662 · Cited by 1,017
Self-citationFasanaro, P., D'Alessandra, Y., Di Stefano, V., Melchionna, R., Romani, S., Pompilio, G., Capogrossi, M. C., & Martelli, F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800731200 · Cited by 912
Cited by
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Chemistry and Biology Of Multicomponent Reactions
Dömling, A., Wang, W., & Wang, K. (2012) · Chemical Reviews · doi:10.1021/cr100233r · Cited by 2,547
Anoikis: an emerging hallmark in health and diseases
Taddei, M., Giannoni, E., Fiaschi, T., & Chiarugi, P. (2012) · The Journal of Pathology · doi:10.1002/path.3000 · Cited by 716
Mechanisms of ephrin–Eph signalling in development, physiology and disease
Kania, A., & Klein, R. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.16 · Cited by 643
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis
Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker-Palmer, A. (2010) · Nature · doi:10.1038/nature08995 · Cited by 534
A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages
Lu, H., Clauser, K. R., Tam, W. L., Fröse, J., Ye, X., Eaton, E. N., Reinhardt, F., Donnenberg, V. S., Bhargava, R., Carr, S. A., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3041 · Cited by 459
Wolfram, J., & Ferrari, M. (2019) · Nano Today · doi:10.1016/j.nantod.2019.02.005 · Cited by 436
Takasugi, M., Okada, R., Takahashi, A., Virya Chen, D., Watanabe, S., & Hara, E. (2017) · Nature Communications · doi:10.1038/ncomms15728 · Cited by 410
Eph Receptor Signaling and Ephrins
Lisabeth, E. M., Falivelli, G., & Pasquale, E. B. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009159 · Cited by 425
Self-citationSpatial regulation of receptor tyrosine kinases in development and cancer
Casaletto, J. B., & McClatchey, A. I. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3277 · Cited by 359
Therapeutic targeting of EPH receptors and their ligands
Boyd, A. W., Bartlett, P. F., & Lackmann, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4175 · Cited by 341
Portrait of the PI3K/AKT pathway in colorectal cancer
Danielsen, S. A., Eide, P. W., Nesbakken, A., Guren, T., Leithe, E., & Lothe, R. A. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.008 · Cited by 321
Cancer exosomes induce tumor innervation
Madeo, M., Colbert, P. L., Vermeer, D. W., Lucido, C. T., Cain, J. T., Vichaya, E. G., Grossberg, A. J., Muirhead, D., Rickel, A. P., Hong, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06640-0 · Cited by 305
Eph Receptors and Ephrins: Therapeutic Opportunities
Barquilla, A., & Pasquale, E. B. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140226 · Cited by 294
Self-citationEph/ephrin molecules—a hub for signaling and endocytosis
Pitulescu, M. E., & Adams, R. H. (2010) · Genes & Development · doi:10.1101/gad.1973910 · Cited by 276
Developmental mechanisms of topographic map formation and alignment
Cang, J., & Feldheim, D. A. (2013) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062012-170341 · Cited by 275
Novel roles for Slits and netrins: axon guidance cues as anticancer targets?
Mehlen, P., Delloye-Bourgeois, C., & Chédotal, A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3005 · Cited by 275
Emerging therapeutic targets in endometrial cancer
Dedes, K. J., Wetterskog, D., Ashworth, A., Kaye, S. B., & Reis-Filho, J. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.216 · Cited by 270
PKB/Akt-Dependent Regulation of Cell Motility
Xue, G., & Hemmings, B. A. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs648 · Cited by 265
Spatial control of membrane receptor function using ligand nanocalipers
Shaw, A., Lundin, V., Petrova, E., Fördős, F., Benson, E., Al-Amin, A., Herland, A., Blokzijl, A., Högberg, B., & Teixeira, A. I. (2014) · Nature Methods · doi:10.1038/nmeth.3025 · Cited by 264
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225
Bone cell interactions through Eph/ephrin: Bone modeling, remodeling and associated diseases
Matsuo, K., & Otaki, N. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20888 · Cited by 167
Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells
Wang, S., Placzek, W. J., Stebbins, J. L., Mitra, S., Noberini, R., Koolpe, M., Zhang, Z., Dahl, R., Pasquale, E. B., & Pellecchia, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201743s · Cited by 94
Self-citationTargeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment
Vail, M. E., Murone, C., Tan, A., Hii, L., Abebe, D., Janes, P. W., Lee, F.-T., Baer, M., Palath, V., Bebbington, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0218 · Cited by 83
“lectin) marking blood-perfused vessels (5, 32).”
BackgroundInfluentialNissinen, L., Farshchian, M., Riihilä, P., & Kähäri, V.-M. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2457-z · Cited by 80
Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery
PosthumaDeBoer, J., Piersma, S. R., Pham, T. V., van Egmond, P. W., Knol, J. C., Cleton-Jansen, A. M., van Geer, M. A., van Beusechem, V. W., Kaspers, G. J. L., van Royen, B. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.578 · Cited by 73
“…that targeting of EPHA2 using www.bjcancer.com |DOI:10.1038/bjc.2013.578 2151 antibodies or RNAi techniques led to reduced tumourigenicity and restored treatment sensitivity in vitro and in vivo (Landen et al, 2005; Hammond et al, 2007; Pasquale, 2010; Tandon et al, 2011; Udayakumar et al, 2011).”
BackgroundMethodInfluentialSalem, A. F., Wang, S., Billet, S., Chen, J.-F., Udompholkul, P., Gambini, L., Baggio, C., Tseng, H.-R., Posadas, E. M., Bhowmick, N. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01837 · Cited by 68
Hsu, K., Middlemiss, S., Saletta, F., Gottschalk, S., McCowage, G. B., & Kramer, B. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-00221-4 · Cited by 51
Promiscuous and specific recognition among ephrins and Eph receptors
Dai, D., Huang, Q., Nussinov, R., & Ma, B. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.07.002 · Cited by 51
Lamberto, I., Qin, H., Noberini, R., Premkumar, L., Bourgin, C., Riedl, S. J., Song, J., & Pasquale, E. B. (2012) · Biochemical Journal · doi:10.1042/bj20120408 · Cited by 48
Self-citationThe Role of Ephs and Ephrins in Memory Formation
Dines, M., & Lamprecht, R. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv106 · Cited by 47
Druggable Orthosteric and Allosteric Hot Spots to Target Protein-protein Interactions
Ma, B., & Nussinov, R. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990073 · Cited by 45
Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine
Quinn, B. A., Wang, S., Barile, E., Das, S. K., Emdad, L., Sarkar, D., De, S. K., Morvaridi, S. K., Stebbins, J. L., Pandol, S. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7931 · Cited by 39
Strimpakos, A., Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Andreadou, A., Sgouros, J., et al. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.07.001 · Cited by 27
A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3
Lahtela, J., Corson, L. B., Hemmes, A., Brauer, M. J., Koopal, S., Lee, J., Hunsaker, T. L., Jackson, P. K., & Verschuren, E. W. (2013) · Cell Cycle · doi:10.4161/cc.23515 · Cited by 20
Investigation of the interactions between the EphB2 receptor and SNEW peptide variants
Ma, B., Kolb, S., Diprima, M., Karna, M., Tosato, G., Yang, Q., Huang, Q., & Nussinov, R. (2014) · Growth Factors · doi:10.3109/08977194.2014.985786 · Cited by 10
Metadata
- Authors
- Pasquale, E. B.
- Venue
- Nature Reviews Cancer
- Published
- 2010-03
- Volume
- 10
- Issue
- 3
- Pages
- 165-180
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1997670728
- Cited by
- 1,226
- References
- 191
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.